Protein Based Amorphous Solid Dispersion: a Case Study Investigating Different Whey Proteins at High Drug Loading

被引:3
|
作者
Leng, Donglei [1 ]
Bulduk, Bulut [1 ]
Widmer, Toni [2 ]
Wiborg, Ole [1 ]
Sanchez-Felix, Manuel [2 ]
Lobmann, Korbinian [1 ]
机构
[1] Zer Pharm AS, Fruebjergvej 3, DK-2100 Copenhagen, Denmark
[2] Sci Novartis Pharm AG, Lichtstr 35, CH-4002 Basel, Switzerland
关键词
amorphous; beta-lactoglobulin; poorly soluble drugs; dissolution; solid dispersion; whey-proteins;
D O I
10.1007/s11095-023-03542-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
PurposeWhey protein isolate (WPI) has previously been shown to be a promising new excipient for the development of amorphous solid dispersions (ASD) at a high drug loading of 50% (w/w). Whilst WPI is a protein mixture, comprising mainly the three proteins beta-lactoglobulin (BLG), alpha-lactalbumin (ALA), casein glycomacropeptides (CGMP), the individual contributions of these three proteins to the overall performance of whey protein based ASDs has still not been investigated. In addition, the limitations of the technology at even higher drug loadings (i.e., more than 50%) have not yet been explored. In this study, BLG, ALA, CGMP and WPI were each prepared as ASDs with the two poorly water-soluble drugs (Compound A and Compound B) at 50%, 60% and 70% drug loadings.MethodsSolid state characterization, dissolution rate and physical stability of the obtained samples were analyzed.ResultsAll the obtained samples were amorphous and showed faster dissolution rates compared to the respective pure crystalline drugs. However, the BLG based formulations-at least for Compound A-were outperforming the other ASDs in terms of stability, dissolution enhancement and solubility increase.ConclusionOverall, the study confirmed that the investigated whey proteins showed their potential in developing ASDs even at high drug loadings of up to 70%.
引用
收藏
页码:1865 / 1872
页数:8
相关论文
共 50 条
  • [21] Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations
    Tian Xie
    Lynne S. Taylor
    Pharmaceutical Research, 2016, 33 : 739 - 750
  • [22] Amorphous solid dispersion of ibuprofen: A comparative study on the effect of solution based techniques
    Ziaee, Ahmad
    O'Dea, Stephen
    Howard-Hildige, Aoise
    Padrela, Luis
    Potter, Catherine
    Iqbal, Javed
    Albadarin, Ahmad B.
    Walker, Gavin
    O'Reilly, Emmet J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 572
  • [23] Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir
    Trasi, Niraj S.
    Bhujbal, Sonal
    Zhou, Qi Tony
    Taylor, Lynne S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2019, 1
  • [24] Role of polymers in the physical and chemical stability of amorphous solid dispersion: A case study of carbamazepine
    Yu, Dongyue
    Li, Jinghan
    Wang, Hanxun
    Pan, Hao
    Li, Ting
    Bu, Tianshi
    Zhou, Wei
    Zhang, Xiangrong
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 169
  • [25] Theoretical evaluation of supersaturation of amorphous solid dispersion formulations with different drug/polymer combinations using mathematical modeling
    Hirai, Daiki
    Tsunematsu, Hiroki
    Kimura, Shin-ichiro
    Itai, Shigeru
    Fukami, Toshiro
    Iwao, Yasunori
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 625
  • [26] Hot Melt Extruded Amorphous Solid Dispersion of Posaconazole with Improved Bioavailability: Investigating Drug-Polymer Miscibility with Advanced Characterisation
    Fule, Ritesh
    Amin, Purnima
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [27] Solvent electrospinning amorphous solid dispersions with high itraconazole, celecoxib, mebendazole and fenofibrate drug loading and release potential
    Becelaere, Jana
    Frateur, Olmo
    Schoolaert, Ella
    Vanhoorne, Valerie
    D'hooge, Dagmar R.
    Vervaet, Chris
    Hoogenboom, Richard
    De Clerck, Karen
    JOURNAL OF CONTROLLED RELEASE, 2023, 362 : 268 - 277
  • [28] Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution
    Thompson, Stephen A.
    Davis Jr, Daniel A.
    Miller, Dave A.
    Kucera, Sandra U.
    Williams III, Robert O.
    BIOMEDICINES, 2023, 11 (05)
  • [29] Investigating the influence of protein secondary structure on the dissolution behavior of ß-lactoglobulin-based amorphous solid dispersions
    Zhuo, Xuezhi
    Tozzetti, Martina
    Arnous, Anis
    Leng, Donglei
    Fodera, Vito
    Lobmann, Korbinian
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
  • [30] Early stages of drug crystallization from amorphous solid dispersion via fractal analysis based on chemical imaging
    Abreu-Villela, Renata
    Schonenberger, Monica
    Caraballo, Isidoro
    Kuentz, Martin
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 133 : 122 - 130